Epithelial ovarian cancer

Ng, Joseph; Low, Jeffrey; Ilancheran, A.

doi:10.1016/j.bpobgyn.2011.12.005

Cited by 44 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients, peritoneal tumor dissemination with ascites is a major cause of cancer-related morbidity and death (2,3). Even with currently recommended chemotherapies, the outcome for ovarian cancer patients with advanced stage is only 12% at 5 years (4,19).…”

Section: Discussionmentioning

confidence: 99%

“…Ovarian adenocarcinoma is responsible for at least 90% of all ovarian malignancies and it is the second most frequent gynecologic malignancy after cervical cancer. Despite various attempts to screen and detect ovarian carcinoma early, over 85% of patients present at an advanced stage which commonly consists of nodal and intraperitoneal dissemination (2). While overall 5 year survival over the last 3 decades has improved from 37% to 46% with a combination of radical surgery and cytotoxic chemotherapy, ovarian cancer remains a major cause of morbidity and mortality for women throughout the world (2,3).…”

Section: Introductionmentioning

confidence: 99%

“…Despite various attempts to screen and detect ovarian carcinoma early, over 85% of patients present at an advanced stage which commonly consists of nodal and intraperitoneal dissemination (2). While overall 5 year survival over the last 3 decades has improved from 37% to 46% with a combination of radical surgery and cytotoxic chemotherapy, ovarian cancer remains a major cause of morbidity and mortality for women throughout the world (2,3). The reasons for this are complex but principally involve the inherent difficulty of safely removing all cancer implants from the peritoneum and the relatively rapid onset of chemo-resistance in advanced stage ovarian cancer (4).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer

Sato

Hanaoka

Watanabe

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Near infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that combines the specificity of intravenously injected antibodies for targeting tumors with the toxicity induced by photosensitizers after exposure to near infrared (NIR) light. Herein, we evaluate the efficacy of NIR-PIT in a mouse model of disseminated peritoneal ovarian cancer. In vitro and in vivo experiments were conducted with a HER2-expressing, luciferase expressing, ovarian cancer cell line (SKOV-luc). An antibody-photosensitizer conjugate (APC) consisting of trastuzumab and a phthalocyanine dye, IRDye-700DX, was synthesized (tra-IR700) and cells or tumors were exposed to near infrared (NIR) light. In vitro PIT cytotoxicity was assessed with dead staining and luciferase activity in freely growing cells and in a 3D spheroid model. In vivo NIR-PIT was performed in mice with tumors implanted in the peritoneum and in the flank and these assessed by tumor volume and/or bioluminescence. In vitro NIR-PIT-induced cytotoxicity was light dose dependent. Repeated light exposures induced complete tumor cell killing in the 3D spheroid model. In vivo the anti-tumor effects of NIR-PIT were confirmed by significant reductions in both tumor volume and luciferase activity in the flank model (NIR-PIT vs control in tumor volume changes at day 10; p=0.0001, NIR-PIT vs control in luciferase activity at day 4; p=0.0237), and the peritoneal model (NIR-PIT vs control in luciferase activity at day 7; p=0.0037). NIR-PIT provided effective cell killing in this HER2 positive model of disseminated peritoneal ovarian cancer. Thus, NIR-PIT is a promising new therapy for the treatment of disseminated peritoneal tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer

Sato

Hanaoka

Watanabe

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…1,2 The annual incidence of EOC exceeded 204,000 cases worldwide and was responsible for approximately 125,000 cancer-related deaths. 3 Although the currently established therapy for ovarian cancer includes radical surgical tumor debulking and subsequent platinum-based chemotherapy, EOC is still associated with the highest case-fatality ratio of all gynecologic cancers partly because of the propensity for early peritoneal dissemination and advanced-stage disease at clinical diagnosis.…”

mentioning

confidence: 99%

Pretreatment Plasma D-Dimer, Fibrinogen, and Platelet Levels Significantly Impact Prognosis in Patients With Epithelial Ovarian Cancer Independently of Venous Thromboembolism

Man

Wang

Hao

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…; Crum ; Ng et al . ). Patients are primarily diagnosed with EOC at an advanced stage, when the tumour has already metastasized or disseminated, making therapeutic options limited (Cannistra ).…”

mentioning

confidence: 97%

Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma

Zhang

Zhu

et al. 2016

Int J Experimental Path

View full text Add to dashboard Cite

Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and therapeutic options for these patients are limited. The identification of suitable biomarkers could be helpful for patients with EOC, who might benefit from targeted therapies even in advanced stages of the disease. Trophoblast cell surface antigen 2 (TROP2) is highly expressed in various human malignant tumours; however, this has not been demonstrated clearly in EOC. In this study, we further evaluated whether TROP2 is a promising marker for EOC, and thus also a potential target for EOC immunotherapy. Quantitative real-time polymerase chain reaction (qPCR) and fluorescence-activated cell sorting (FACS) analysis were employed to determine TROP2 mRNA and protein expression in both human EOC and normal ovarian cell lines. Additionally, TROP2 protein expression was measured by immunohistochemistry in 128 EOC tissue samples, 21 normal ovarian tissues and 18 normal fallopian tubes. The correlations between TROP2 protein expression and patients' clinicopathological features were investigated, and survival outcomes were analysed. TROP2 mRNA and protein levels were upregulated significantly in EOC cell lines compared with normal cell lines. The protein of TROP2 was expressed in the majority of EOC tissue samples (90.6%) and overexpressed in 75 (58.6%) of the 128 tumour samples. TROP2 overexpression was correlated with relevant clinicopathological characteristics and was associated with significantly shortened overall survival and disease-free survival. Furthermore, TROP2 was an independent prognostic marker for EOCs as analysed by Cox regression. TROP2 was a potential biomarker for targeted therapy in patients with TROP2-overexpressing EOC.

show abstract

Epithelial ovarian cancer

Cited by 44 publications

References 33 publications

Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer

Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer

Pretreatment Plasma D-Dimer, Fibrinogen, and Platelet Levels Significantly Impact Prognosis in Patients With Epithelial Ovarian Cancer Independently of Venous Thromboembolism

Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma

Contact Info

Product

Resources

About